Early detection and risk reduction for familial gynecologic cancers

Clinical Obstetrics and Gynecology

Volumn 41, Issue 1, 1998, Pages 200-214

  Chen, Lee May ^a   Karlan, Beth Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONFERENCE PAPER; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER;

COLORECTAL NEOPLASMS; FEMALE; GENETIC SCREENING; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; RISK;

EID: 0031943689     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199803000-00025     Document Type: Conference Paper

References (101)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1997. Cancer J Clin. 1997;47:5-27.
2. Boyd J, Rubin SC. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol. 1997;64:196-206.
3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
4. Lynch HT, Lanspa SJ, Boman BM, et al. Hereditary nonpolyposis colorectal cancer - Lynch Syndromes I and II. Gastroenterol Clin North Am. 1988;17(4): 679-712.
5. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D, and the Collaborative Ovarian Cancer Group. Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol. 1994;84(5):760-764.
6. Schildkraut JM, Thompson WD. Familial ovarian cancer: A population-based casecontrol study. Am J Epidemiol. 1988; 128(3):456-466.
7. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992;80(4):700-707.
8. Lynch HT, Albano W, Black L, Lynch JF, Recarbaren J, Pierson R. Familial excess of cancer of the ovary and other anatomic sites. JAMA. 1981;245(3):261-264.
9. Lynch HT, Watson P, Bewtra C, et al. Hereditary ovarian cancer. Cancer. 1991; 67(5):1460-1466.
10. Lynch HT, Harris RE, Giurgis HA, Maloney K, Carmody LL, Lynch JF. Familial association of breast/ovarian carcinoma. Cancer, 1978;41(4):1543-1549.
11. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the 17q-linked breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
12. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium, Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet. 1993; 52:678-701.
13. Wooster R, Bignall G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378: 789-792.
14. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13:123-125.
15. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333-337.
16. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11:198-200.
17. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60:505-514.
18. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
19. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496-504.
20. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997; 336(16):1125-1130.
21. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet. 1995; 9:439-443.
22. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germline BRCA1 mutations in Jewish and non-Jewish women with earlyonset breast cancer. N Engl J Med. 1996;334(3):143-149.
23. Langsten AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334(3):137-142.
24. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11:428-433.
25. Gayther SA, Mangion J, Russell P, et al. Variation of risks or breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15:103-105.
26. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56:265-271.
27. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. Risks of cancer of BRCA1 mutation carriers. Lancet. 1994; 343:692-695.
28. Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer. 1971; 27:1505.
29. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71(3):677-685.
30. Hakala T, Mecklin J-P, Forss M, Jarvinen H, Lehtovirta P. Endometrial carcinoma in the cancer family syndrome. Cancer. 1991;68(7):1656-1659.
31. Aarnio M, Mecklin J-P, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Lifetime risk of different cancers in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430-435.
32. Menko FH, Wijnen JT, Khan PM, Vasen HFA, Oosterwijk MH. Genetic counseling in hereditary nonpolyposis colorectal cancer. Oncology. 1996;10(1):71-76.
33. Aaltonen LA, Peltomaki, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1995;260:812-816.
34. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 260:810-812.
35. Lindblom A, Tannergard P, Werelius B, et al. Genetic mapping of a second locus predisposing to hereditary nonpolyposis colon cancer. Nat Genet. 1993;5:279-282.
36. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homologue MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027-1038.
37. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLHl is associated with hereditary nonpolyposis colon cancer. Nature. 1994;368:258-261.
38. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994;371:75-80.
39. Sandles LG, Shulman LP, Elias S, et al. Endometrial adenocarcinoma: Genetic analysis suggesting site-specific uterine cancer. Gynecol Oncol. 1992;47:167-171.
40. Gruber SB, Thompson WD, and the CASH Study Group. A population-based study of endometrial cancer and familial risk in younger women. Cancer Epidemiol Biomarkers Prev. 1996;5:411-417.
41. Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136(10):1184-1203.
42. Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 U.S. case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidmiol. 1992;136:1212-1220.
43. Narod SA, Goldgar D, Cannon-Albright L, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer. 1995; 64:394-398.
44. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317-1325.
45. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771-776.
46. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz R, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 1996; 65(1):13-18.
47. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril. 1996;66(4):499-507.
48. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992;80(4):708-714.
49. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med. 1987; 316(11):650-655.
50. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 1994;83(3):419-424.
51. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980; 302(10):551-554.
52. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA. 1987;257(6):796-800.
53. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87(11):827-835.
54. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst. 1996;88(6):365-371.
55. Ursin G, Henderson BE, Haile RW, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/ BRCA2 mutations more than in other women? Cancer Res. 1997;57(17):3678-3681.
56. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA. 1993;270(23): 2813-2816.
57. Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc. Cancer. 1982;50(2):372-376.
58. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, MD: Williams & Wilkins, 1996:73-103, 159-166, 625-642, 755-764.
59. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: Critical review and meta-analyses of the epidemiologic evidence. J Natl Cancer Inst. 1990;82(8):650-661.
60. Thun MJ, Calle EE, Namboordiri MM, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992;84( 19):1491-1500.
61. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancer of the colon and rectum: Evidence for the combined analysis of 13 case-control studies. J Natl Cancer Inst. 1992;84(24):1887-1896.
62. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991; 325(23):1593-1596.
63. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85(15):1220-1224.
64. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333(10):609-614.
65. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328:1313-1316.
66. Early Breast Cancer Trialists' Collarborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med. 1988;319(26):1681-1692.
67. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991;83(20):1450-1459.
68. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-452.
69. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifentreated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527-537.
70. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst, 1995; 87(9):645-651.
71. Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol. 1996; 39(3):629-640.
72. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet. 1995;49:241-257.
73. Hann LE, Giess CS, Bach AM, Baum HJ, Bakarat RR. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings. Am J Radiol. 1997;168:657-661.
74. DePalo G, Veronesi U, Camerini T, et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst. 1995;87(2):146-147.
75. Averette HE, Nguyen HN. The role of prophylactic oophorectomy in cancer prevention. Gynecol Oncol. 1994;55:S38-S41.
76. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465-1471.
77. Tobacman JK, Tucker MA, Kase R, Greene MH, Costa J, Fraumeni JF, Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982:795-797.
78. Bandera C, Muto M, Berkowitz R, Rubin S, Boyd J, Mok S. Germline BRCA1 mutations in women with papillary serous carcinoma of the peritoneum (PSCP). Proceedings of the Annual Meeting of the American Association for Cancer Research. 1997;38:A549.
79. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst. 1993;85(20): 1644-1656.
80. Breast Cancer Screening for Women Ages 40-49. NIH Consensus Development Conference Statement Online. January 21-23, 199714(2):1-11.
81. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA. 1997;277(12):997-1003.
82. Fleischer DE, Goldberg SB, Browning TH, et al. Detection and surveillance of colorectal cancer. JAMA. 1989;261(4):580-585.
83. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology. 1997;112:594-642.
84. Vasen HFA, Taal BG, Griffioen G, et al. Clinical heterogeneity of familial colo- rectal cancer and its influence on screening protocols. Gut. 1994;35:1262-1266.
85. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA. 1997;277(11):915-919.
86. Koss LG, Schreiber K, Oberlander SG, Moussouris HF, Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol. 1984;64(1):1-11.
87. Gronroos M, Salmi RA, Vuento MH, et al. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer. 1993;71(4):1279-1282.
88. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: Screening, treatment, and follow-up. Gynecol Oncol. 1994;55:S4-S14.
89. Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol. 1994;55:S28-S33.
90. Jacobs I, Bast RC. The CA125 tumor-associated antigen: A review of the literature. Hum Reprod. 1989;4(1):1-12.
91. Skates SJ, Xu F, Yu Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10):2004-2010.
92. Jacobs I, Bridges J, Reynolds C, et al. Multimodal approaches to screening for ovarian cancer. Lancet. 1988;i:269-271.
93. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ. 1993;306:1030-1034.
94. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE, A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol. 1996;65:221-225.
95. Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: Rationale, protocol design, and early results. Am J Obstet Gynecol. 1993;169(3):494-501.
96. Muto MG, Cramer DW, Brown DL, et al. Screening for ovarian cancer: The preliminary experience of a familial ovarian cancer center. Gynecol Oncol. 1993;51:12-20.
97. Childers JM, Hatch KD, Surwit EA. Office laparoscopy and biopsy for evaluation of patients with intraperitoneal carcinomatosis using a new optical catheter. Gynecol Oncol. 1992;47:337-342.
98. Canis M, Mage G, Pouly JL, Wattiez A, Manhes H, Bruhat MA. Laparoscopic diagnosis of adnexal cystic masses: A 12-year experience with long-term follow-up. Obstet Gynecol. 1994;83:707-712.
99. Nezhat F, Nezhat C, Welander CE, Benigno B. Four ovarian cancers diagnosed during laparoscopic management of 1,011 women with adnexal masses. Am J Obstet Gynecol. 1992;167:790-796.
100. Kruitwagen RFPM, Swinkels BM, Keyser KGG, Doesburg WH, Schijf CPT. Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer. Gynecol Oncol. 1996;60:233-237.
101. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute Sponsored Screening Trial for Prostatic, Lung, Colorectal, and Ovarian Cancers. Cancer. 1993;71(2):589-593.